5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | NEUTRAL | NEUTRAL | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 50.75▲ | 50.52▲ | 50.62▲ | 51.39▼ | 40.43▲ |
MA10 | 50.62▲ | 50.73▲ | 51.28▼ | 48.07▲ | 26.73▲ |
MA20 | 50.46▲ | 51.37▼ | 51.39▼ | 38.72▲ | 18.77▲ |
MA50 | 50.66▲ | 51.59▼ | 49.41▲ | 23.21▲ | 15.21▲ |
MA100 | 51.32▼ | 48.90▲ | 45.40▲ | 16.80▲ | 15.27▲ |
MA200 | 51.39▼ | 44.91▲ | 30.98▲ | 14.56▲ | 12.81▲ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.071▲ | -0.133▼ | -0.368▼ | 0.556▲ | 4.703▲ |
RSI | 59.820▲ | 46.515▼ | 50.375▲ | 87.834▲ | 90.004▲ |
STOCH | 94.475▲ | 20.639 | 15.716▼ | 87.166▲ | 87.358▲ |
WILL %R | -7.317▲ | -73.050 | -79.974▼ | -19.142▲ | -6.962▲ |
CCI | 115.223▲ | -36.237 | -79.810 | 91.867 | 139.286▲ |
Saturday, August 16, 2025 05:13 AM
Q2 2025 Earnings Call Transcript August 15, 2025 Operator: Good afternoon, ladies and gentlemen, and welcome to the Celcuity Second Quarter 2025 Financial Results Webcast and Conference Call.
|
Friday, August 15, 2025 08:41 AM
Get key takeaways from Celcuity's Q2 2025 earnings call, featuring positive Phase III trial data, $5B market potential for gedatolisib, and FDA plans ...
|
Friday, August 15, 2025 12:38 AM
Despite increased losses, Celcuity Inc (CELC) makes significant strides in clinical trials and secures funding for future growth.
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
18/08/25 | 52.68 | 52.68 | 50.06 | 50.82 | 391,501 |
15/08/25 | 52.92 | 53.855 | 50.861 | 51.79 | 908,871 |
14/08/25 | 50.89 | 52.15 | 49.995 | 51.89 | 1,813,355 |
13/08/25 | 50.33 | 53.40 | 49.50 | 52.37 | 979,645 |
12/08/25 | 46.94 | 50.33 | 46.82 | 50.06 | 959,954 |
11/08/25 | 45.88 | 47.355 | 45.09 | 46.66 | 1,069,100 |
08/08/25 | 44.43 | 48.00 | 44.16 | 45.88 | 1,326,123 |
07/08/25 | 44.22 | 44.98 | 42.885 | 44.24 | 649,219 |
06/08/25 | 42.69 | 44.97 | 42.38 | 44.19 | 835,139 |
05/08/25 | 43.00 | 44.24 | 42.28 | 42.84 | 1,312,978 |
|
|
||||
|
|
||||
|
|